Cytochrome P450 enzymes and drug-drug interactions: An update on the superfamily

Journal of Pharmacy Technology

Volumn 22, Issue 1, 2006, Pages 22-31

  Lewis, Jeffrey D ^a   Bachmann, Kenneth A ^b  

^a Lexi Comp Inc   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMINOPHYLLINE; AMIODARONE; CAFFEINE; CARRIER PROTEIN; CODEINE; CYCLOBENZAPRINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DEXMEDETOMIDINE; GLIMEPIRIDE; GLIPIZIDE; GLYCOPROTEIN P; METOPROLOL; OMEPRAZOLE; PACLITAXEL; PAROXETINE; PENTAMIDINE; PHENOBARBITAL; PROTON PUMP INHIBITOR; RETINOIC ACID; ROSIGLITAZONE; SULFONAMIDE; THEOPHYLLINE; TIOTIXENE; TIZANIDINE; UNINDEXED DRUG; WARFARIN;

ARTICLE; BOOK; DIAGNOSTIC KIT; DRUG INTERACTION; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME POLYMORPHISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FOOD DRUG INTERACTION; GENETIC VARIABILITY; GRAPEFRUIT JUICE; HEALTH PRACTITIONER; INTERNET; MEDICAL LITERATURE; MEDLINE; PREDICTION; PROTEIN FAMILY;

EID: 32544453841     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250602200105     Document Type: Article

References (53)

1. Malone DC, Abarca J, Hansten PD, et al. Identification of serious drug-drug interactions: results of the Partnership to Prevent Drug-Drug Interactions. J Am Pharm Assoc 2004;44:142-51.
2. Conney AH, Levin W, Ikeda M, Kuntzman R, Cooper DY, Rosenthal O. Inhibitory effect of carbon monoxide on the hydroxylation of testosterone by rat liver microsomes. J Biol Chem 1958;243:3912-5.
3. Wada F, Shimakawa H, Takasugi M, Kotake T, Sakamoto Y. Effect of steroid hormones on drug-metabolizing enzyme systems in liver microsomes. J Biochem 1968;64:109-13.
4. Pederson TC, Aust SD. Aminopyrine demethylase. Kinetic evidence for multiple microsomal activities. Biochem Pharmacol 1970;19:2221-30.
5. Cytochrome P450 stats, http://drnelson.utmem.edu/P450.statsfile. html (accessed 2005 Feb 22).
6. Guengerich FP. Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 2004;36:159-97.
7. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;52:2211-21.
8. Clarke SE, Jones BC. Human cytochromes P450 and their role in metabolism-based drug-drug interactions. In: Rodrigues AD, ed. Drug-drug interactions. New York: Marcel Dekker, 2002:55-88.
9. Greenblatt DJ, von Moltke LL. Sedative-hypnotic and anxiolytic agents. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, eds. Metabolic drug interactions. Philadelphia: Lippincott, Williams & Wilkins, 2000:259-70.
10. Omura T, Sato R. A new cytochrome in liver microsomes. J Biol Chem 1962;237:1375-6.
11. Garfinkel D. Studies on pig liver microsomes. I. Enzymic and pigment composition of different microsomal fractions. Arch Biochem Biophys 2003;409:7-15.
12. Klingenberg M. Pigments of rat liver microsomes. Arch Biochem Biophys 2003;409:2-6.
13. Nebert DW, Adesnik M, Coon MJ, et al. The P450 gene superfamily: recommended nomenclature. DNA 1987;6:1-11.
14. Nebert DW, Nelson DR, Adesnik M, et al. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 1989;8:1-13.
15. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily - update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51.
16. Haining RL, Yu A. Cytochrome P450 pharmacogenetics. In: Lee JS, Obach RS, Fisher MB, eds. Drug metabolizing enzymes. Cytochrome P450 and other enzymes in drug discovery and development. Lausanne, Switzerland: Fontis Media, 2003:375-419.
17. Cytochrome P450s in humans. http://drnelson.utmem.edu/P450lect. html (accessed 2004 Sep 10).
18. The P450 catalytic cycle, www.tcm.phy.cam.ac.uk/~mds21/thesis/node49.html (accessed 2005 Feb 21).
19. Lewis DF. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human P450 substrate specificity and metabolism. Biochem Pharmacol 2000;60:293-306.
20. Bachmann KA, Lewis JD, Fuller MA, Bonfiglio MF, eds. Lexi-Comp's Lexi-Interact database. Hudson, OH: Lexi-Comp, Inc., 2005.
21. Goodwin B, Redinbo MR, Kliewer SA. Regulation of CYP3A gene transcription by the pregnane X receptor. Annu Rev Pharmacol Toxicol 2002;42:1-23.
22. Watkins RE, Wisely GB, Moore LB, et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001;292:2329-33.
23. Xie W, Barwick JL, Simon CM, et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 2000;14:3014-23.
24. Kliewer SA, Moore JT, Wade L, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998;92:73-82.
25. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-23.
26. Jones SA, Moore LB, Shenk JL, et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000;14:27-39.
27. Burk O, Wojnowski L. Cytochrome P450 3A and their regulation. Nauyn-Schmiedebergs Arch Pharmacol 2004;369:105-24.
28. Forman BM, Tzameli I, Choi HS, et al. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 1998;395:612-5.
29. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98.
30. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc National Acad Sci U S A 1996;93:4001-5.
31. Ekins S, Mirny L, Schuetz EG. A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha and LXRbeta. Pharm Res 2002;19:1788-800.
32. Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 2001;29:1644-51.
33. Galetin A, Clarke SE, Houston JB. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 2002;30:1512-22.
34. Ekins S, Stresser DM, Williams A. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 2003;24:161-6.
35. Hutzler JM, Hauer MJ, Tracy TS. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab Dispos 2001;29:1029-34. Erratum. 2001;29:1171.
36. Madan A, Usuki E, Burton LA, Ogilvie BW, Parkinson A. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In: Rodrigues AD, ed. Drug-drug interactions. New York: Marcel Dekker, 2002:217-94.
37. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003;43:443-69.
38. Bachmann KA, Lewis JD. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 2005;39:1064-72. Epub 10 May 2005. DOI 10.1345/aph.1E508
39. Shou M. Prediction of drug-drug interactions from mechanism-based inhibition of cytochrome P450. Presented at: the 6th International Conference on Drug-Drug Interactions, Institute for Scientific Exchange, June 23-25, 2003, San Diego, CA.
40. Hollenberg P. Mechanism-based inactivation of cytochrome P450s: potential for drug-drug interactions. Presented at: the 6th International Conference on Drug-Drug Interactions, Institute for Scientific Exchange, June 23-25, 2003, San Diego, CA.
41. Zhang Y, Benet LZ. The gut as a barrier to drug absorption. Clin Pharmacokinet 2001;40:159-68.
42. Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993;36:457-9.
43. Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6′,7′- Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999;65:237-44.
44. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995;345:955-6.
45. Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997;62:348-54.
46. Barditch-Crovo P, Trapnell CB, Ette E, et al. A pharmacokinetic and pharmacodynamic evaluation of the effect of rifampin and rifabutin on combination oral contraceptives. Clin Pharmacol Ther 1999;65:428-38.
47. Kumana CR, Tong MK, Li CS, et al. Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin. Br J Clin Pharmacol 2003;56:670-8.
48. Pai MP, Schriever CA, Diaz-Linares M, Novak RM, Rodvold KA. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy 2004;24:592-9.
49. Pulido F, Katlama C, Marquez M, et al. A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults. HIV Med 2004;5:296-302.
50. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-37.
51. Brynne N, Forslund C, Hallen B, Gustafsson L, Bertilsson L. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 1999;48:564-72.
52. Guengerich FP. Cytochromes P450, drugs, and diseases. Mol Interv 2003;3:194-204.
53. Roche's AMPLICHIP CYP450 test receives FDA clearance, www. roche-diagnostics.com/press_lounge/press_releases/2005_01_12.html (accessed 2005 Jan 17).